Expect Equity LLC Makes New Investment in Bruker Corporation $BRKR

Expect Equity LLC bought a new position in Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, HoldingsChannel reports. The fund bought 70,930 shares of the medical research company’s stock, valued at approximately $4,269,000. Bruker makes up approximately 2.7% of Expect Equity LLC’s portfolio, making the stock its 5th largest holding.

A number of other institutional investors have also recently made changes to their positions in BRKR. Orbis Allan Gray Ltd increased its position in shares of Bruker by 5.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after acquiring an additional 761,258 shares in the last quarter. Pallas Capital Advisors LLC bought a new position in Bruker in the 2nd quarter valued at approximately $570,746,000. State Street Corp lifted its position in Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after acquiring an additional 91,706 shares in the last quarter. AQR Capital Management LLC boosted its stake in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Finally, Sculptor Capital LP boosted its stake in Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after purchasing an additional 270,000 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Stock Down 0.2%

Shares of BRKR stock opened at $56.85 on Wednesday. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30. The stock has a market cap of $8.66 billion, a P/E ratio of -81.21, a P/E/G ratio of 1.74 and a beta of 1.28. The company has a 50 day simple moving average of $58.69 and a two-hundred day simple moving average of $47.71.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same period in the prior year, the business posted $0.32 EPS. Bruker’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s payout ratio is currently -28.57%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BRKR. Citigroup decreased their price target on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Leerink Partners lifted their price objective on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Stifel Nicolaus set a $50.00 target price on Bruker in a research report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.64.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.